Delcath Systems
Delcath Systems' revenue rose 129.1% to $85 million in fiscal 2025. Its operating margin was 0.8%, up from −33.4% a year earlier. Free cash flow was $21 million. It paid out $6 million in dividends and buybacks, 29% of free cash flow. The diluted share count rose 40.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Delcath Systems does
Delcath Systems is an interventional oncology company, which means it treats cancer through procedures guided by imaging. It focuses on cancers in the liver, either starting there or spreading to it. Its lead product, the HEPZATO KIT, combines the chemotherapy drug melphalan with a device that delivers it directly to the liver. The FDA approved it in August 2023 for adults with a type of eye melanoma that has spread to the liver, and the first commercial use was in January 2024.
In Europe, the same delivery device is sold on its own as CHEMOSAT, without the drug. Delcath took over sales, marketing and distribution of CHEMOSAT there in March 2022. It reports one operating segment.
The company says it has limited experience as a commercial company and is trying to build revenue from HEPZATO. It has one melphalan supplier now and is in talks with others. It says it has stockpiled inventory and uses several suppliers for key parts to manage supply risk.
Its biggest risks, as it describes them
- It has lost money since it started, and continuing losses could use up its capital.
- It has limited experience selling products and may never be profitable if HEPZATO does not succeed.
- It has an agreement with just one supplier of melphalan.
- If it cannot make CHEMOSAT and HEPZATO successfully, it could not develop and sell them.
- Product liability claims or recalls, and lawsuits, could hurt its business.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 23 | 8 | 32 | 53 | 91 |
| Debt incl. finance leases | 5 | 16 | 10 | 0 | 0 |
| Net debt (negative means net cash) | −18 | 8 | −22 | −53 | −91 |
| Net debt to EBITDA | — | — | — | — | −101.4x |
| Debt to equity | 0.4x | — | 0.6x | 0.0x | 0.0x |
| Interest coverage | −36.0x | −18.1x | −26.2x | −10.0x | — |
| Current ratio | 5.2x | 1.1x | 2.3x | 12.0x | 10.9x |
| Quick ratio | 5.0x | 1.0x | 2.1x | 10.9x | 10.0x |
Cash flow
Projections
Project Delcath Systems' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Delcath Systems says to expect
- Full year 2026: revenue
Increases 2026 Revenue Guidance to a Range of $115 million to $117 million
Insider trades
No officer, director or 10% owner of Delcath Systems reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 6 of 9 | 6 of 9 |
| Rule of 40 | −1,540.2% | 1,650.0% | 153.7% |
| Altman Z'' | −45.05 | −8.72 | 1.26 |
| Accruals ratio | −58.2% | −13.4% | −19.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 6 of 9 | 6 of 9 |
Compare
Put Delcath Systems side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | |
| IRADIMED | FY25 | 14.4% | 31.2% | 20.5% | — | — | — | Compare |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | Compare |
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 3 | — | — | — | 4 | 3 | 2 | 37 | 85 |
| Revenue growth | 14.0% | 36.3% | — | — | — | — | −23.5% | −24.1% | 1,701.7% | 129.1% |
| Gross profit | 1 | 2 | 2 | 1 | 1 | 3 | 2 | 1 | 31 | 73 |
| Research and development | 8 | 10 | 20 | 10 | 11 | 14 | 19 | 18 | 14 | 29 |
| Operating income | −16 | −18 | −27 | −20 | −21 | −24 | −34 | −38 | −12 | 1 |
| Net income | −18 | −45 | −19 | −9 | −24 | −26 | −36 | −48 | −26 | 3 |
| Diluted EPS (US$) | −3,707.00 | −3,250.00 | −0.72 | −342.83 | −8.35 | −3.59 | −4.12 | −2.94 | −0.93 | 0.07 |
| Diluted shares (millions) | 5 | 14 | 27 | 26 | 3 | 7 | 9 | 16 | 28 | 40 |
| Cash flow | ||||||||||
| Cash from operations | −14 | −15 | −15 | −24 | −23 | −23 | −25 | −31 | −19 | 22 |
| Capital expenditure | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Free cash flow | −14 | −16 | −15 | −24 | −24 | −23 | −25 | −31 | −19 | 21 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | — | — | — | 8 | 8 | 10 | 24 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 4 | 4 | 2 | 10 | 29 | 23 | 8 | 32 | 53 | 91 |
| Debt incl. finance leases | — | — | 0 | 2 | 0 | 5 | 16 | 10 | 0 | 0 |
| Total assets | 35 | 9 | 7 | 14 | 35 | 33 | 18 | 39 | 77 | 124 |
| Total liabilities | 37 | 8 | 22 | 21 | 13 | 21 | 24 | 23 | 8 | 12 |
| Shareholders' equity | −2 | 1 | −15 | −6 | 22 | 12 | −6 | 16 | 69 | 111 |
| Margins and ratios | ||||||||||
| Gross margin | 72.4% | 74.2% | — | — | — | 81.1% | 74.8% | 69.2% | 83.4% | 86.2% |
| Operating margin | −825.3% | −669.1% | — | — | — | −690.0% | −1,245.0% | −1,849.0% | −33.4% | 0.8% |
| Net margin | −902.2% | −1,661.8% | — | — | — | −721.5% | −1,342.7% | −2,308.9% | −70.9% | 3.2% |
| Free cash flow margin | −726.5% | −586.5% | — | — | — | −639.9% | −925.3% | −1,516.2% | −51.7% | 24.6% |
| Rule of 40 (growth + FCF margin) | −712.4% | −550.1% | — | — | — | — | −948.8% | −1,540.2% | 1,650.0% | 153.7% |
| Return on capital | — | — | — | — | — | — | — | — | — | 2.8% |
| Return on equity | −505.4% | — | — | — | −307.3% | −150.7% | −1,198.4% | −961.4% | −62.4% | 3.0% |
| Return on assets | −70.5% | −204.5% | −244.4% | −84.3% | −98.9% | −75.7% | −143.2% | −168.8% | −45.8% | 2.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | −101.4x |